These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24569469)

  • 1. Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales.
    Chamberlain C; Collin SM; Stephens P; Donovan J; Bahl A; Hollingworth W
    Br J Cancer; 2014 Oct; 111(9):1693-702. PubMed ID: 24569469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain.
    Linley WG; Hughes DA
    Health Econ; 2013 Aug; 22(8):948-64. PubMed ID: 22961976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund.
    Aggarwal A; Fojo T; Chamberlain C; Davis C; Sullivan R
    Ann Oncol; 2017 Aug; 28(8):1738-1750. PubMed ID: 28453615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. At last, NICE to take over the Cancer Drugs Fund.
    Timmins N
    BMJ; 2016 Mar; 352():i1324. PubMed ID: 26951838
    [No Abstract]   [Full Text] [Related]  

  • 5. Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
    Morrell L; Wordsworth S; Schuh A; Middleton MR; Rees S; Barker RW
    BMC Health Serv Res; 2018 May; 18(1):393. PubMed ID: 29855313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NHS England drops 16 medicines from Cancer Drugs Fund.
    Hawkes N
    BMJ; 2015 Sep; 351():h4803. PubMed ID: 26345321
    [No Abstract]   [Full Text] [Related]  

  • 7. "What's fair to an individual is not always fair to a population": A qualitative study of patients and their health professionals using the Cancer Drugs Fund.
    Chamberlain C; Owen-Smith A; MacKichan F; Donovan JL; Hollingworth W
    Health Policy; 2019 Aug; 123(8):706-712. PubMed ID: 31279588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
    Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
    JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Cancer Drugs Fund is flawed without NICE reform, says Roche.
    Hawkes N
    BMJ; 2016 Jul; 354():i4216. PubMed ID: 27473207
    [No Abstract]   [Full Text] [Related]  

  • 10. The Cancer Drugs Fund in Practice and Under the New Framework.
    Sabry-Grant C; Malottki K; Diamantopoulos A
    Pharmacoeconomics; 2019 Jul; 37(7):953-962. PubMed ID: 30941698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer drugs dropped from 'unsustainable' fund list.
    Nurs Stand; 2015 Sep; 30(4):10. PubMed ID: 26394942
    [No Abstract]   [Full Text] [Related]  

  • 12. Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs.
    Pinto A; Naci H; Neez E; Mossialos E
    Value Health; 2020 Mar; 23(3):319-327. PubMed ID: 32197727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in cancer drug assessment between Spain and the United Kingdom.
    Lozano-Blázquez A; Dickson R; Fraga-Fuentes MD; Martínez-Martínez F; Calleja-Hernández MÁ
    Eur J Cancer; 2015 Sep; 51(13):1843-52. PubMed ID: 26119375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New "managed access" process for Cancer Drugs Fund to go ahead, NHS England confirms.
    Mayor S
    BMJ; 2016 Feb; 352():i1208. PubMed ID: 26926879
    [No Abstract]   [Full Text] [Related]  

  • 15. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Has NICE been nice to cancer?
    Summerhayes M; Catchpole P
    Eur J Cancer; 2006 Nov; 42(17):2881-6. PubMed ID: 17070032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales.
    Trowman R; Chung H; Longson C; Littlejohns P; Clark P
    Clin Cancer Res; 2011 Aug; 17(15):4930-5. PubMed ID: 21791636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Did It Matter That the Cancer Drugs Fund Was Not NICE? A Retrospective Review.
    Dixon P; Chamberlain C; Hollingworth W
    Value Health; 2016; 19(6):879-884. PubMed ID: 27712717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Tale of Two Thresholds: A Framework for Prioritization within the Cancer Drugs Fund.
    Leigh S; Granby P
    Value Health; 2016; 19(5):567-76. PubMed ID: 27565274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NICE and the Cancer Drugs Fund--2020 vision?
    Drug Ther Bull; 2016 Apr; 54(4):37. PubMed ID: 27056193
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.